Cynosure announces the US Food and Drug Administration (FDA) clearance of the Potenza radiofrequency (RF) microneedling device, a four-mode RF microneedling device that offers clinicians versatility and personalized treatments for patients.

The Potenza device’s four modes (monopolar or bipolar, delivered at either 1 MHz or 2 MHz frequency) offer customized microneedling treatments and allow practitioners to deliver both shallow and deep treatments on a single system.

The device’s monopolar RF mode delivers energy across a large area of tissue for deep heating and skin tightening through soft tissue coagulation, not only on the face, but anywhere on the body. The bipolar RF mode offers more concentrated delivery of energy to treat superficial tissue and provide ideal skin revitalization results.

The device is also equipped with Tiger Tip technology, reportedly the first semi-insulated needles of its design which allow practitioners to expand the treatment zone and address more tissue per treatment, which translates to quicker sessions for patients, without sacrificing the epidermis. The device is also armed with a single-needle handpiece designed to target and improve blemishes, a media release from Cynosure explains. 

“Our goal at Cynosure is to provide our customers with revolutionary technologies so they can consistently deliver outstanding results,” says Todd Tillemans, Chief Executive Officer of Cynosure.

“Potenza takes the microneedling category to a new level by offering unprecedented flexibility for doctors, which translates to personalized treatments and satisfied patients with exceptional outcomes.”

Potenza treatments use ultrafine needles and radiofrequency energy to penetrate the top layer of the skin and trigger the body’s natural healing process to regenerate new collagen and elastin. Potenza treatments can be performed on all skin types, anywhere on the body and any time of year, the release continues.

[Source(s): Cynosure, PR Newswire]